Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies

Journal of Microencapsulation

Volumn 29, Issue 7, 2012, Pages 615-625

  Fuchs, Sebastian ^a   Klier, John ^a   May, Anna ^a   Winter, Gerhard ^a   Coester, Conrad ^a   Gehlen, Heidrun ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Aerosol; Gelatin; Immunology; Nanoparticle; Oligonucleotides; Pulmonary drug delivery

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GELATIN; INTERLEUKIN 10; NANOCARRIER; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGIC FACTOR; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE;

AEROSOL; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL NEBULIZER; METERED DOSE INHALER; NONHUMAN; PARTICLE SIZE; VIBRATING MESH NEBULIZER; ANIMAL; CHEMISTRY; HORSE; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS; METABOLISM; METHODOLOGY;

ADMINISTRATION, INHALATION; ANIMALS; GELATIN; HORSES; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-10; MALE; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PULMONARY ALVEOLI;

EID: 84868704899     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.668962     Document Type: Article

References (41)

1. Beck-Broichsitter M, Gauss J, Packhaeuser C, Lahnstein K, Schmehl T, Seeger W, Kissel T, Gessler T. Pulmonary drug delivery with aerosoliz-Able nanoparticles in an ex vivo lung model. Int J Pharm, 2009;367(1-2):169-78.
2. Bernstein IL. Bronchoalveolar lavage in asthma-"something old, something new..". J Allergy Clin Immunol, 1984;7(1):22-5. (Pubitemid 14093021)
3. Bourquin C, Anz D, Zwiorek K, Lanz A, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol, 2008;181(5):2990-8.
4. Butz N, Porte C, Courrier H, Krafft MP, Vandamme Th. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. Int J Pharm, 2002;238(1-2):257-69. (Pubitemid 34457894)
5. Coester CJ, Langer K, Von Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation-A new preparation method, surface modifications and cell uptake. J Microencapsulation, 2000;17(2):187-93. (Pubitemid 30135796)
6. Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Rel, 2003;86(1):131-44. (Pubitemid 35461980)
7. Dhand R. New frontiers in aerosol delivery. Respir Care, 2004;49(6):666-77.
8. Elhissi AMA, Karnam KK, Nesh-Azari MR, Gill HS, Taylor KMG. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J Pharm Pharmacol, 2006;58(7):887-94. (Pubitemid 43967104)
9. Elhissi AMA, Taylor KMG. Delivery of liposomes generated from prolipo-somes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J Drug Delivery Sci Technol, 2005;15(4):261-5. (Pubitemid 41223726)
10. Finlay WH, Roa W, Loebenberg R. 2005. Formulation of powder containing nanoparticles for aerosol delivery to the lungs. Patent Application Publication US 2005019270.
11. Fuchs S, Winter G, Coester C. Ultrasonic resonator technology as a new quality control method evaluating gelatin nanoparticles. J Microencapsul, 2010;27(3):242-52.
12. Ghazanfari T, Elhissi A, Ding Z, Taylor K. The influence of fluid physico-chemical properties on vibrating-mesh nebulization. Int J Pharm, 2007;339(1-2):103-11. (Pubitemid 46977598)
13. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nano-particles for lung protein delivery. Eur J Pharm Sci, 2005;25(4-5):427-37. (Pubitemid 40853870)
14. Hadinoto K, Zhu K, Tan RBH. Drug release study of large hollow nanopar-ticulate aggregates carrier particles for pulmonary delivery. Int J Pharm, 2007;341(1-2):195-206. (Pubitemid 47088103)
15. Haroon A, Waldrep JC, Dhand R. 2005. Could vibrating mesh/aperture plate nebulizers be used for human Alpha-1 Anti-Proteinase Inhibitor (hA1PI) replacement therapy? Proceedings of American Thoracic Society annual meeting, 20-25 May 2005, San Diego, California.
16. Hoffman AM. Bronchoalveolar lavage: Sampling technique and guidelines for cytologic preparation and interpretation. Vet Clin North Am Equine Pract, 2008;24(2):423-35. (Pubitemid 352001364)
17. Horohov DW, Beadle RE, Mouch S, Pourciau SS. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction. Vet Immunol Immunopathol, 2005;108:237-45. (Pubitemid 41319698)
18. Jackson KA, Stott JL, Horohov DW, Watson JL. IL-4 induced CD23 (Fc.vepsiln.RII) up-regulation in equine peripheral blood mononuclear cells and pulmonary alveolar macrophages. Vet Immunol Immunopathol, 2004;101(3-4):243-50. (Pubitemid 39178382)
19. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxy-nucleotides as TLR9 agonists for immune modulation. BioDrugs, 2007;21(6):387-401. (Pubitemid 350145447)
20. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Rel, 1999;62(1-2):279-87. (Pubitemid 29486508)
21. Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int J Pharm, 1999;186(1):81-90. (Pubitemid 29397525)
22. Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, Johnson J, Englert S, Ketterer T, Heckl W, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-Alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem, 2005;280(9):8086-93. (Pubitemid 40349707)
23. Klier J, May A, Fuchs S, Schillinger U, Plank C, Winter G, Gehlen H, Coester C. Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-Affected horses by different CpG-classes bound to gelatin nanoparticles. J Microencap, 2011;144:79-97.
24. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Disc, 2006;5(6):471-84. (Pubitemid 44136959)
25. Kunzle F, Gerber V, Van der Haegen A, Wampfler B, Straub R, Marti E. IgE-bearing cells in bronchoalveolar lavage fluid and allergen-specific IgE levels in sera from RAO-Affected horses. J Vet Med, 2007;A 54(1):40-7. (Pubitemid 46156880)
26. Lentz YK, Anchordoquy TJ, Lengsfeld CS. Rationale for the selection of an aerosol delivery system for gene delivery. J Aerosol Med, 2006;19(3):372-84. (Pubitemid 44735393)
27. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm, 2008;356(1-2):333-44.
28. Nyambura BK, Kellaway IW, Taylor KMG. Insulin nanoparticles: Stability and aerosolization from pressurized metered dose inhalers. Int J Pharm, 2009;375(1-2):114-22.
29. Purewal TS. Alternative propellants for metered dose inhalers. Aerosol Spray Rep, 1998;37(11/12):20-5. (Pubitemid 29028559)
30. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocar-riers for pulmonary drug delivery. Expert Opin Drug Delivery, 2008;5(6):629-39. (Pubitemid 351998253)
31. Sato H, Ueberreiter K. Surface tension of aqueous gelatin solution. Polym Prepr, Am Chem Soc, Div Polym Chem, 1979;20(1):907-8.
32. Sham JOH, Zhang Y, Finlay WH, Roa WH, Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm, 2004;269(2):457-67. (Pubitemid 38045308)
33. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed, 2008;3(1):1-19. (Pubitemid 351517072)
34. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol, 2007;25(12):563-70. (Pubitemid 350138179)
35. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF- modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials, 2009;30(20):3476-85.
36. Tseng CL, Wang TW, Dong GC, Wu SYH, Young TH, Shieh MJ, Lou PJ, Lin FH. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 2007;28(27):3996-4005.
37. 3 nanofluids. Nanotechnology, 2009;20(18):185702-1-185702-6.
38. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, Williams ROI. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 2006;63(2):95-102. (Pubitemid 43776206)
39. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Delivery, 2008;5(2):114-19. (Pubitemid 351536317)
40. Zillies JC, Zwiorek K, Hoffmann F, Vollmar A, Anchordoquy TJ, Winter G, Coester C. Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles. Eur J Pharm Biopharm, 2008;70(2):514-21.
41. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res, 2008;25(3):551-62. (Pubitemid 351357729)